PA-CENCORA
14.5.2024 15:36:33 CEST | Business Wire | Press release
Cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene Therapy (CGT) Summit, an event designed to explore the latest developments in the CGT sector and strategies to accelerate product commercialization and patient access.
The two-day virtual event, which kicks off May 14, will feature panel discussions and presentations that cover key topics and considerations across the commercialization journey — from clinical manufacturing and channel strategy to the solutions needed to support efficient global launches, navigate the unique supply chain requirements, and overcome barriers along the patient journey. The event will feature perspectives from a wide range of leaders, including experts from companies that have launched or are developing a CGT as well as representatives from patient advocacy groups, trade associations, and the U.S. Food and Drug Administration (FDA).
“We are entering a new era in cell and gene therapy — with new modalities reaching the market and a growing number of products in clinical development, including therapies that target larger patient populations. However, the path to commercialization is complex and lined with potential challenges that can impact product success and patient access,” said Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at Cencora. “By bringing together this group, our goal is to foster collaboration and advance best practices that will support the development and commercialization of these groundbreaking therapies and help to ensure they can reach the patients who need them.”
There are nearly 2,000 CGT clinical trials underway globally, according to the Alliance for Regenerative Medicine (ARM). In the United States and Europe, there could be as many as 17 regulatory decisions on CGTs in 2024.
During Cencora’s summit, industry experts will examine strategies to overcome barriers at each stage of the product lifecycle — from research and clinical development (R&D) to global commercialization and patient engagement strategies. The event will be capped by a fireside chat with ARM’s Chief Operating Officer Rita Johnson-Greene, who will reflect on the progress seen in the last five years and offer her perspective on what she expects will happen during the next half-decade.
A leader in specialty distribution and services, Cencora offers CGT developers support at each stage of the product lifecycle, including third-party logistics services, regulatory consulting, market access and reimbursement support, clinical trial and commercial distribution, and patient support services. Through its CGT Integration Hub, Cencora connects provider-facing platforms with patient services support programs to increase visibility across the therapy development and delivery process, streamlining the path-to-care.
“We believe the next five years hold tremendous promise for this market and patients worldwide, and we continue to invest in solutions to elevate the support we offer to developers to help them bring their products to market,” said Willis Chandler, President of Global Pharma Services at Cencora. “Launching this summit reflects our belief in the promise of cell and gene therapies, as well as our commitment to create a more connected CGT ecosystem and unlock the potential of these therapies.”
For more information or to register for the event, visit: https://www.cencora.com/campaign/gps/thinklive-2024-cgt-summit.
About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at investor.cencora.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508817695/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verdantis Rebrands as the AI Super-Agent for MRO, Sets Sights on AI-Native Enterprise Asset Management8.9.2026 16:06:00 CEST | Press release
Nine AI agents now run the MRO decision chain for Fortune 500 plants; new tagline “Anticipate. Resolve. Learn.” Verdantis, the AI company for spare parts and MRO inventory optimization in asset-intensive industries, today unveiled its new brand identity as the AI Super-agent for MRO and announced it is building toward a fully AI-native Enterprise Asset Management (EAM) platform. Verdantis’s super-agent orchestrates nine specialized AI agents across the decisions that decide plant uptime: spare parts, criticality, demand, reorder, and work order planning. These decisions set working capital, maintenance spend, and whether a critical asset runs and, in most plants, they are still made in spreadsheets and disconnected systems. The positioning is for the teams who own uptime - maintenance, reliability, and MRO supply chain leaders in oil and gas, mining, utilities, chemicals, and manufacturing. And it reflects an AI-first architecture: agents decide and act by default; people supervise, ov
HyperLight Welcomes VentureTech Alliance to Series C, Deepening TFLN Integration Across the Semiconductor Ecosystem8.9.2026 16:00:00 CEST | Press release
HyperLight Corporation ("HyperLight"), a leader in thin-film lithium niobate (TFLN) photonics, today announced that VentureTech Alliance ("VTA") has joined its Series C financing round. VTA is a venture investment firm focused on the semiconductor industry, with a portfolio built across the semiconductor technology stack — including circuit design, foundry-adjacent process technology, EDA, advanced packaging, and photonics. VTA's participation extends the ecosystem alignment that defined the round, which brought together investors spanning silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure capital. With VTA's addition, the syndicate now reaches further into the semiconductor manufacturing and design-enablement layers on which high-volume photonics production depends. "The transition to TFLN is not a component decision — it is an ecosystem decision," said Mian Zhang, CEO of HyperLight. "Getting TFLN into volume requires the proc
EcoOnline Appoints Conor O’Loughlin as CEO8.9.2026 16:00:00 CEST | Press release
O’Loughlin brings founder, product and commercial experience spanning startup growth, global SaaS scale and M&A EcoOnline, a global provider of software that transforms how organisations protect people and the planet, today announced the appointment of Conor O’Loughlin as Chief Executive Officer, effective immediately. O’Loughlin succeeds Tom Goodmanson and will lead the Company into its next chapter of growth and innovation, continuing EcoOnline’s mission of keeping employees safe across the globe and supporting more than 11,000 customers. O’Loughlin is an experienced, growth-oriented technology operator and founder. He co-founded fitness technology company Glofox, scaling it into a global SaaS business serving customers in more than 80 countries before its acquisition by ABC Fitness in 2022. Following the acquisition, he served as Platform President and later Global Chief Revenue Officer at ABC Fitness, leading strategy across the company’s revenue-generating activities. “Keeping peo
Hawker Operators Gain Access to High-Speed Starlink Connectivity Through Textron Aviation Customer Support Network8.9.2026 16:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced Starlink’s high-speed internet is now available for the Hawker 700, 800 and 900 series aircraft, following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC). The STC includes the Starlink Aviation Performance Kit, which utilizes Starlink’s advanced constellation of Low Earth Orbit (LEO) satellites to help customers stay connected throughout their journey with more reliability over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908170569/en/ Hawker operators gain access to high-speed Starlink connectivity through Textron Aviation Customer Support network “Hawker operators continue to look to Textron Aviation for long-term care and upgrade solutions that ensure their aircraft remain mission-ready in today’s operat
Nanochon Performs First Case in the Chondrograft™ First-in-Human Clinical Study8.9.2026 15:47:00 CEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the treatment of articular cartilage defects of the knee, today announced the successful treatment of the first patient in its First-in-Human (FIH) clinical study. The study is designed to evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee. Dr. Juan Osorio and Dr. Emilio Tufiño, who both specialize in regenerative sports medicine, performed the first procedure at The Panama Clinic, Panamá. “I am pleased to be the Principal Investigator for this important study, and we are excited to be the first to initiate clinical study enrollment. The team here in Panamá looks forward to contributing the data that will support a larger clinical study and subsequent market entry,” stated Dr. Osorio. “The speed at which Dr. Osorio and the clinical team were able to identify, enroll, and treat the first patient underscores the significant unmet clini
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom